89: Thyroid Cancer Web Sites Confuse Patients with Dr. Rashika Bansal from St. Joseph’s Regional Medical Center

In this episode Dr. Bansal shares the research she presented at AACE 2017 and ENDO 2017, regarding the poor readability scores for thyroid cancer web sites. The challenge for these web sites and health institutions is to translate thyroid education from complex to simple and easy to understand. Currently, many patients are not following up with treatment, citing confusion after being exposed to the various thyroid cancer education resources.

Continue Reading

85: A Summary of Radioactive Iodine Treatment for Thyroid Cancer, with Dr. Alan Waxman from Cedars Sinai

Not all thyroid cancer patients who receive a thyroidectomy require radioactive iodine, but for those whose cancer maybe more aggressive and spread beyond the thyroid area, often radioactive iodine (RAI) is protocol. RAI treatment may vary depending on the hospital. In this interview, Dr. Alan Waxman explains what occurs leading up to, during, and after RAI. Topics discussed include: If staying at the hospital after taking RAI, how long is the stay required? Should you go home after RAI? What is the benefit of staying overnight at the hospital when receiving RAI? Worldwide trends toward prescribing lower doses of RAI. Is there risk in RAI causing leukemia?

Continue Reading

79: No Biopsy is 100% Accurate⎥Molecular Testing Gets Close, with Dr. Bridget Brady from Austin Thyroid Surgeons

Dr. Bridget Brady is Austin's first fellowship-trained endocrine surgeon. In this episode the following topics are discussed: Austin Thyroid Surgeons sees 30 patients per week with thyroid nodules Up to 80% of US population could have a thyroid nodule(s) less than 5% of Dr Brady's thyroid nodule patients test positive for cancer How relevant is what I don’t know won’t hurt me in thyroid cancer and biopsies of nodules? BETHESDA system or the middle category, also known as indeterminate For thyroid nodules that are indeterminate, historically a surgery would be performed  With molecular testing, surgery can be decreased by up to 50% Afirma molecular testing uses messenger RNA If Afirma comes back suspicious it does NOT necessarily mean it is cancer

Continue Reading

75: Thyroid Cancer Does Not Respond to RAI⎢Treatment Options

In this episode, topics include: * Drug therapy for patients that fail standard therapy; including surgery and RAI * Not all patients have same behavior for their cancer * Some cancers are aggressive * Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands * What is the treatment protocol for therapy? * Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer * Lenvatinib tends to be more effective * Sorafenib is tolerated by the patient better * Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF * BRAF inhibitors used with thyroid cancer patients * Molecular profiling * DNA sequencing

Continue Reading
Close Menu

Subscribe to Doctor Thyroid with Philip James Newsletter

No spam. Your information is safe.
It will not be shared with any third party.
You can unsubscribe at any time.